The U.S. Centers for Disease Control and Prevention's revamped vaccine advisory panel on Wednesday postponed its vote on the use of respiratory syncytial virus therapies to Thursday. The panel, which ...

At the start of today’s meeting, ACIP's new chair, Martin Kulldorff, PhD, a statistician and epidemiologist formerly at Harvard University, announced that there will be changes to the membership of ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

FDA approval of Merck’s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi’s Beyfortus. The new Merck product is expected to be discussed by the CDC’s Advisory Committee on ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...